Human hallucinogen research: guidelines for safety - PubMed
Review
Human hallucinogen research: guidelines for safety
Mw Johnson et al. J Psychopharmacol. 2008 Aug.
Abstract
There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the study site. Less common are prolonged psychoses triggered by hallucinogens. Safeguards against these risks include the exclusion of volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, establishing trust and rapport between session monitors and volunteer before the session, careful volunteer preparation, a safe physical session environment and interpersonal support from at least two study monitors during the session. Investigators should probe for the relatively rare hallucinogen persisting perception disorder in follow-up contact. Persisting adverse reactions are rare when research is conducted along these guidelines. Incautious research may jeopardize participant safety and future research. However, carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.
Figures
Similar articles
-
Who takes the trip? Personality and hallucinogen use among college students and adolescents.
Parnes JE, Kentopp SD, Conner BT, Rebecca RA. Parnes JE, et al. Drug Alcohol Depend. 2020 Dec 1;217:108263. doi: 10.1016/j.drugalcdep.2020.108263. Epub 2020 Aug 30. Drug Alcohol Depend. 2020. PMID: 32932162
-
Halpern JH. Halpern JH. Curr Psychiatry Rep. 2003 Oct;5(5):347-54. doi: 10.1007/s11920-003-0067-4. Curr Psychiatry Rep. 2003. PMID: 13678554 Review.
-
[Hallucinogen-induced psychological disorders].
Hermle L, Kovar KA, Hewer W, Ruchsow M. Hermle L, et al. Fortschr Neurol Psychiatr. 2008 Jun;76(6):334-42. doi: 10.1055/s-2008-1038191. Fortschr Neurol Psychiatr. 2008. PMID: 18512184 Review. German.
-
Regulation of human research with LSD in the United States (1949-1987).
Bonson KR. Bonson KR. Psychopharmacology (Berl). 2018 Feb;235(2):591-604. doi: 10.1007/s00213-017-4777-4. Epub 2017 Nov 17. Psychopharmacology (Berl). 2018. PMID: 29147729 Review.
-
A regulatory perspective on the evaluation of hallucinogen drugs for human use.
Calderon SN, Hunt J, Klein M. Calderon SN, et al. Neuropharmacology. 2018 Nov;142:135-142. doi: 10.1016/j.neuropharm.2017.11.028. Epub 2017 Nov 24. Neuropharmacology. 2018. PMID: 29180224 Review.
Cited by
-
Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R. Breeksema JJ, et al. Sci Rep. 2024 Feb 5;14(1):2929. doi: 10.1038/s41598-024-53188-9. Sci Rep. 2024. PMID: 38316896 Free PMC article. Clinical Trial.
-
Prediction of psilocybin response in healthy volunteers.
Studerus E, Gamma A, Kometer M, Vollenweider FX. Studerus E, et al. PLoS One. 2012;7(2):e30800. doi: 10.1371/journal.pone.0030800. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363492 Free PMC article. Clinical Trial.
-
Psychedelic-Assisted Therapy: Emerging Treatments in Mental Health Disorders.
Penn A, Dorsen CG, Hope S, Rosa WE. Penn A, et al. Am J Nurs. 2021 Jun 1;121(6):34-40. doi: 10.1097/01.NAJ.0000753464.35523.29. Am J Nurs. 2021. PMID: 33993135 Free PMC article.
-
Legal highs: staying on top of the flood of novel psychoactive substances.
Baumeister D, Tojo LM, Tracy DK. Baumeister D, et al. Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539. Ther Adv Psychopharmacol. 2015. PMID: 26240749 Free PMC article. Review.
-
Use of psychedelics in the Czech Republic: results of recent population surveys.
Chomynová P, Kočárová R, Kňažek F, Plevková M, Bláhová B, Valeš K, Mravčík V. Chomynová P, et al. Cent Eur J Public Health. 2022 Sep;30(3):144-153. doi: 10.21101/cejph.a7079. Cent Eur J Public Health. 2022. PMID: 36239361
References
-
- Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction. 1993;88:1327–1334. - PubMed
-
- Abramson HA, editor. The Use of LSD in Psychotherapy. New York: Josiah Macy Jr. Foundation Publications; 1960.
-
- Abramson HA, editor. The Use of LSD in Psychotherapy and Alcoholism. New York: Bobbs-Merrill; 1963.
-
- Abuzzahab FS, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychiat. 1971;6:223–235. - PubMed
-
- American Psychiatric Association. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials